Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes
- 1 December 2014
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (24), 5624-5635
- https://doi.org/10.1111/bph.12864
Abstract
Tamoxifen is a prodrug that is metabolically activated by 4-hydroxylation to the potent primary metabolite 4-hydroxytamoxifen (4OHT) or via another primary metabolite N-desmethyltamoxifen (NDMTAM) to a biologically active secondary metabolite endoxifen through a cytochrome P450 2D6 variant system (CYP2D6). To elucidate the mechanism of action of tamoxifen and the importance of endoxifen for its effect, we determined the anti-oestrogenic efficacy of tamoxifen and its metabolites, including endoxifen, at concentrations corresponding to serum levels measured in breast cancer patients with various CYP2D6 genotypes (simulating tamoxifen treatment). The biological effects of tamoxifen and its metabolites on cell growth and oestrogen-responsive gene modulation were evaluated in a panel of oestrogen receptor-positive breast cancer cell lines. Actual clinical levels of tamoxifen metabolites in breast cancer patients were used in vitro along with actual levels of oestrogens observed in premenopausal patients taking tamoxifen. Tamoxifen and its primary metabolites (4OHT and NDMTAM) only partially inhibited the stimulant effects of oestrogen on cells. The addition of endoxifen at concentrations corresponding to different CYP2D6 genotypes was found to enhance the anti-oestrogenic effect of tamoxifen and its metabolites with an efficacy that correlated with the concentration of endoxifen; at concentrations corresponding to the extensive metabolizer genotype it further inhibited the actions of oestrogen. In contrast, lower concentrations of endoxifen (intermediate and poor metabolizers) had little or no anti-oestrogenic effects. Endoxifen may be a clinically relevant metabolite in premenopausal patients as it provides additional anti-oestrogenic actions during tamoxifen treatment.Keywords
Funding Information
- National Institutes of Health (P30 CA051008)
- U.S. Department of Defense (W81XWH-06-1-0590)
- Susan G. Komen for the Cure (SAC100009)
- German Research Foundatrion (MU1727/2-1)
This publication has 40 references indexed in Scilit:
- Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-EstrogensPLOS ONE, 2013
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2012
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer PatientsJNCI Journal of the National Cancer Institute, 2012
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 TrialJNCI Journal of the National Cancer Institute, 2012
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter StudyJournal of Clinical Oncology, 2011
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancerSteroids, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenograftsEuropean Journal of Cancer and Clinical Oncology, 1989